BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001737523 · BGLC · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001737523 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
No recent filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
BioNexus Gene Lab Corp. (NASDAQ: BGLC) has submitted 141 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001737523, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is BioNexus Gene Lab Corp.'s most comprehensive regulatory disclosure. The most recent BioNexus Gene Lab Corp. 10-K was filed on 2026-04-14 for fiscal year ending 2026. Historical BGLC 10-K annual reports are available from 2019 through 2026.
Investors researching BioNexus Gene Lab Corp. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
BGLC SEC Filings · 8 questionsBioNexus Gene Lab Corp. (BGLC) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 141 filings and access original documents at no cost. BioNexus Gene Lab Corp.'s CIK is 0001737523.